Treatment with rituximab and brentuximab vedotin in a patient of common variable immune deficiency-associated classic Hodgkin lymphoma

Biomarker Research

Volumn 4, Issue 1, 2016, Pages

  Rael, Efren ^a   Rakszawski, Kevin ^b   Koller, Kristian ^b   Bayerl, Michael ^c   Butte, Manish ^a   Zheng, Hong ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Brentuximab; CVID; Hodgkin lymphoma; Rituximab

Indexed keywords

BRENTUXIMAB VEDOTIN; CD15 ANTIGEN; CD20 ANTIGEN; CD30 ANTIGEN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; TRANSCRIPTION FACTOR PAX5;

ADULT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CLASSICAL HODGKIN LYMPHOMA; COMMON VARIABLE IMMUNODEFICIENCY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; FEMALE; FEVER; FLANK PAIN; FOLLOW UP; GRANULOMATOUS INFLAMMATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHADENOPATHY; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 85010773498     PISSN: None     EISSN: 20507771     Source Type: Journal    
DOI: 10.1186/s40364-016-0061-8     Document Type: Article

References (22)

1. Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112:277-86.
2. Cunningham-Rundles C. How I, treat common variable immune deficiency. Blood. 2010;116:7-15.
3. Vajdic CM, Mao L, van Leeuwen MT, Kirkpatrick P, Grulich AE, Riminton S. Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency? Blood. 2010;116:1228-34.
4. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92:34-48.
5. Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012;119:1650-7.
6. Aghamohammadi A, Rezaei N, Gharagozlou M, et al. Hodgkin lymphoma in two siblings with common variable immunodeficiency. Pediatr Hematol Oncol. 2007;24:337-42.
7. Kaplan B, Kopyltsova Y, Khokhar A, Lam F, Bonagura V. Rituximab and immune deficiency: case series and review of the literature. J Allergy Clin Immunol In Pract. 2014;2:594-600.
8. Saini KS, Azim Jr HA, Cocorocchio E, et al. Rituximab in Hodgkin lymphoma: is the target always a hit? Cancer Treat Rev. 2011;37:385-90.
9. Anagnostopoulos I, Hansmann ML, Franssila K, et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood. 2000;96:1889-99.
10. Rassidakis GZ, Medeiros LJ, Viviani S, et al. CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. J Clin Oncol. 2002;20:1278-87.
11. Oki Y, Younes A. Does rituximab have a place in treating classic hodgkin lymphoma? Curr Hematol Malig Rep. 2010;5:135-9.
12. Jones RJ, Gocke CD, Kasamon YL, et al. Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood. 2009;113:5920-6.
13. Bartlett NL, Chen R, Fanale MA, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014;7:24.
14. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30:2183-9.
15. Gobert D, Bussel JB, Cunningham-Rundles C, et al. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol. 2011;155:498-508.
16. Mellemkjaer L, Hammarstrom L, Andersen V, et al. Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin Exp Immunol. 2002;130:495-500.
17. Cunningham-Rundles C. Hematologic complications of primary immune deficiencies. Blood Rev. 2002;16:61-4.
18. Gangemi S, Allegra A, Musolino C. Lymphoproliferative disease and cancer among patients with common variable immunodeficiency. Leuk Res. 2015;39:389-96.
19. Bienemann K, Borkhardt A, Klapper W, Oschlies I. High incidence of Epstein-Barr virus (EBV)-positive Hodgkin lymphoma and Hodgkin lymphoma-like B-cell lymphoproliferations with EBV latency profile 2 in children with interleukin-2-inducible T-cell kinase deficiency. Histopathology. 2015;67:607-16.
20. Ardeniz O, Cunningham-Rundles C. Granulomatous disease in common variable immunodeficiency. Clin Immunol. 2009;133:198-207.
21. Cunningham-Rundles C. Common variable immunodeficiency. Curr Allergy Asthma Rep. 2001;1:421-9.
22. Morimoto Y, Routes JM. Granulomatous disease in common variable immunodeficiency. Curr Allergy Asthma Rep. 2005;5:370-5.